Fiztasovimab(TD-VK665026) is a research-grade recombinant antibody targetingEnvelope glycoprotein B. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5)
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Human
Isotype
IgG1, lambda2
Clonality
Monoclonal
Target
Envelope glycoprotein B, gB, UL55
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06473
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
NPC21, NPC-21, NPC21, 2467411-25-0
Background
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
Caption
SDS-PAGE for Research Grade Fiztasovimab.
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询